other material
confidence high
sentiment positive
materiality 0.75
Tyra Biosciences expands TYRA-300 into achondroplasia with positive preclinical data; TYRA-200 IND cleared
Tyra Biosciences, Inc.
- TYRA-300 increased body length by 17.6% in FGFR3 Y367C/+ mice (p<0.0001); femur +24.4%, tibia +38.3%, L4-L6 +23.9%.
- Company plans to submit IND for Phase 2 study in pediatric achondroplasia in 2024.
- FDA cleared IND for TYRA-200, an FGFR1/2/3 inhibitor; first patient dosing expected H2 2023.
- Compensation Committee adopted annual incentive plan; CEO target bonus 50% of base salary, other execs 40%.